Financing
Share Buybacks
Neurocrine Biosciences Share Buybacks increased by 205.1% to $54.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 64.0%, from $150.00M to $54.00M.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
How to read this metric
High repurchases often signal management's confidence in the company's valuation or a strategy to improve earnings per share.
Detailed definition
The cash outflow associated with the company buying back its own shares from the open market. This is a primary method f...
Peer comparison
Common among mature, cash-generative companies; peers in the healthcare sector often balance this with R&D investment.
Metric ID:
share_repurchasesHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $300.00M | $150.00M | $17.70M | $54.00M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | — | -50.0% | -88.2% | +205.1% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -64.0% |
Range$0.00 – $300.00M
Avg YoY Growth-64.0%
Median YoY Growth-64.0%
Share Buybacks at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's share buybacks?
- Neurocrine Biosciences (NBIX) reported share buybacks of $54.00M in Q1 2026.
- How has Neurocrine Biosciences's share buybacks changed year-over-year?
- Neurocrine Biosciences's share buybacks decreased by 64.0% year-over-year, from $150.00M to $54.00M.
- What does share buybacks mean?
- Cash spent by the company to buy back its own stock.